Replies to post #34232 on Marker Therapeutics Inc (MRKR)

[Phantom Lord]

He replied to my email earlier this month. I inquired about a few things one being the strategic review and for what its worth I received a copy and paste of the answer he provided you a couple months ago. I've probably sent two emails the whole year though. Maybe you are sending too many? He obviously has a lot to do so I'm not surprised some emails go unanswered. My personal opinion is the more you send the more likely they will be ignored. Especially if they contain the same questions over and over again.

As far as major news goes, we already know roughly what to expect by the end of the year.

1. Strategic review. (Barring any delay from the FDA as this is what I believe is holding up the review since it will involve changes to existing trials the FDA needs to approve them. We can't get the update with out that)
2. MRD data.
3. Lymphoma data.
4. Potential pancreatic trial grant. (This doesn't really have a date on it but it was referenced earlier this year)

Anything outside of that would be a surprise and probably unlikely. I also wouldn't consider any of the above major news. We'll see how this all shakes out.

[microcapbiotech]

I only emailed him that one time and he answered very quickly. They say (whoever "they" are) that no news is good news, but in this case, no news is driving me crazy. I just hope he has some good news by the end of this year like everybody is expecting.
I know that he can't give us any info until he has it all to give, but this waiting game is getting old (again). If the share price gets below $2.25 I'll buy some more (like an idiot), but unless that, I'm done buying more and just holding (like how many times have I said that before over these many years).